Rapid Dose Therapeutics (XCNQ:DOSE) Cash And Cash Equivalents : C$0.07 Mil (As of Aug. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics Cash And Cash Equivalents?

Rapid Dose Therapeutics's quarterly cash and cash equivalents declined from Feb. 2024 (C$0.16 Mil) to May. 2024 (C$0.11 Mil) but then stayed the same from May. 2024 (C$0.11 Mil) to Aug. 2024 (C$0.07 Mil).

Rapid Dose Therapeutics's annual cash and cash equivalents declined from Feb. 2022 (C$0.03 Mil) to Feb. 2023 (C$0.03 Mil) but then increased from Feb. 2023 (C$0.03 Mil) to Feb. 2024 (C$0.16 Mil).

Rapid Dose Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Rapid Dose Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Cash And Cash Equivalents Chart

Rapid Dose Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.07

0.03

0.16

Rapid Dose Therapeutics Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.20	0.17	0.16	0.11	0.07

Rapid Dose Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Rapid Dose Therapeutics (XCNQ:DOSE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Rapid Dose Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

RDTCF:USA

Address

1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4

Website

https://www.rapid-dose.com

Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

Executives

Mark Upsdell	Director
Brian Howlett	Director

Rapid Dose Therapeutics Headlines

No Headlines